0001662002-17-000001.txt : 20171116 0001662002-17-000001.hdr.sgml : 20171116 20171116141624 ACCESSION NUMBER: 0001662002-17-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171116 DATE AS OF CHANGE: 20171116 EFFECTIVENESS DATE: 20171116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nohla Therapeutics Inc. CENTRAL INDEX KEY: 0001662002 IRS NUMBER: 475261773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-275626 FILM NUMBER: 171207699 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 61430589444 MAIL ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 D/A 1 primary_doc.xml X0708 D/A LIVE 0001662002 Nohla Therapeutics Inc. 1616 EASTLAKE AVENUE EAST SUITE 360 SEATTLE WA WASHINGTON 98102 61430589444 DELAWARE Cytomatrix Therapeutics, Inc. None Corporation true 2015 Lawrence Gozlan 1616 Eastlake Avenue East Suite 360 Seattle WA WASHINGTON 98102 Director Michael Sistenich 1616 Eastlake Avenue East Suite 360 Seattle WA WASHINGTON 98102 Director Steven Gillis 1616 Eastlake Avenue East Suite 360 Seattle WA WASHINGTON 98102 Director Brian Daniels 1616 Eastlake Avenue East Suite 360 Seattle WA WASHINGTON 98102 Director Kathleen Fanning 1616 Eastlake Avenue East Suite 360 Seattle WA WASHINGTON 98102 Executive Officer Director Biotechnology Decline to Disclose 06b true 0001662002-16-000002 2016-11-18 true true true false 0 41515869 32356803 9159066 These amounts exclude issuances of Company securities pursuant to Regulation S promulgated under the Securities Act of 1933, as amended false 13 0 0 0 false Nohla Therapeutics Inc. /s/ Tom Swallow Tom Swallow Vice President, Finance & Administration 2017-11-16